Published in Oncologist on March 23, 2010
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
The biological and therapeutic relevance of mRNA translation in cancer. Nat Rev Clin Oncol (2011) 1.54
Rapalogs in cancer prevention: anti-aging or anticancer? Cancer Biol Ther (2012) 1.40
Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist (2011) 1.22
Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther (2012) 1.09
Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol (2014) 0.96
Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review. Chemother Res Pract (2012) 0.87
Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Adv Urol (2012) 0.86
The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention. BMC Vet Res (2012) 0.83
Quantitative medical cost-effectiveness analysis of molecular-targeting cancer drugs in Japan. Daru (2013) 0.83
Oral Mucositis Induced By Anticancer Therapies. Curr Oral Health Rep (2015) 0.83
Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment. Oncotarget (2015) 0.82
Eukaryotic initiation factor 2α--a downstream effector of mammalian target of rapamycin--modulates DNA repair and cancer response to treatment. PLoS One (2013) 0.82
Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia. Cancer Biol Ther (2015) 0.80
mTOR Inhibitors at a Glance. Mol Cell Pharmacol (2016) 0.80
Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates. Med Res Rev (2015) 0.78
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. Oncotarget (2016) 0.78
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist (2014) 0.78
Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors. Anticancer Drugs (2013) 0.77
Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Haematologica (2015) 0.77
Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis. PLoS One (2013) 0.76
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget (2016) 0.76
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer (2017) 0.75
The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials. BBA Clin (2015) 0.75
Therapeutic interventions to disrupt the protein synthetic machinery in melanoma. Pigment Cell Melanoma Res (2015) 0.75
Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. Br J Clin Pharmacol (2016) 0.75
Temsirolimus: is improved survival the correct expression of drug activity? Oncologist (2010) 0.75
Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer. Int J Mol Sci (2017) 0.75
The Role of Angiogenesis in Cancer Treatment. Biomedicines (2017) 0.75
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet (1999) 4.72
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res (2007) 2.94
Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res (2006) 2.65
Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol (1999) 2.45
Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist (2007) 2.17
Surgery of renal cell carcinoma. Urol Clin North Am (1993) 1.20
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist (2007) 4.95
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med (2011) 3.77
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol (2010) 3.49
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist (2003) 3.28
Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol (2004) 3.18
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist (2009) 3.18
End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol (2003) 2.98
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res (2007) 2.94
Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst (2011) 2.74
Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med (2012) 2.69
Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res (2006) 2.65
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res (2002) 2.56
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist (2003) 2.53
Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res (2007) 2.47
United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res (2004) 2.43
Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist (2009) 2.37
Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res (2004) 2.24
Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist (2007) 2.17
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res (2006) 2.07
Accelerated approval of oncology products: a decade of experience. J Natl Cancer Inst (2004) 2.07
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park) (2009) 2.06
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res (2002) 2.06
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist (2007) 1.94
Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res (2005) 1.93
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res (2008) 1.82
FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist (2005) 1.81
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol (2008) 1.71
FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist (2005) 1.66
Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park) (2009) 1.63
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res (2007) 1.62
U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist (2013) 1.52
Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013. Cancer (2014) 1.51
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist (2008) 1.49
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res (2010) 1.46
FDA drug approval summary: panitumumab (Vectibix). Oncologist (2007) 1.44
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res (2012) 1.41
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist (2007) 1.38
FDA drug approval summaries: pemetrexed (Alimta). Oncologist (2004) 1.37
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res (2005) 1.36
U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res (2012) 1.31
Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res (2013) 1.31
Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues. Stat Methods Med Res (2008) 1.30
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol (2007) 1.29
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res (2003) 1.29
FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist (2007) 1.29
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res (2005) 1.28
U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res (2013) 1.27
FDA drug approval summaries: oxaliplatin. Oncologist (2004) 1.25
Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist (2010) 1.25
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist (2010) 1.24
FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol (2007) 1.20
FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist (2008) 1.17
Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin Cancer Res (2008) 1.17
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol (2007) 1.16
Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res (2003) 1.12
FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist (2005) 1.12
U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res (2014) 1.12